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ABSTRACT
Hepatitis A virus (HAV), a positive-strand RNA virus, is stable at moderate temperature and low pH level. 
These characteristics allow the virus to survive in the environment and be transmitted through fecal-oral route.
Twenty-year-old male came with jaundice and itchy skin since one month before admission. He was diagnosed 
as hepatitis A cholestasis type according to his history taking, physical examination, and laboratory result. Blood 
test showed elevated total bilirubin 27.4 g/dL, direct bilirubin 21.2 g/dL, indirect bilirubin 6.2 g/dL, alanin 
aminotransferase (ALT) 95 U/L, aspartate transaminase (AST) 134 U/L, alkaline phosphatase (ALP) 221 U/L, 
and gamma-glutamyltransferase (gGT) 17 U/L. His ultrasound results showed mild, non-specific hepatomegaly 
without common bile duct dilatation. The patient got symptomatic therapy with ursodeoxycholic acid (UDCA) 
300 mg twice daily for his itchy skin and steroid therapy 0.5-1 mg/kg per day on the tenth day. He did not vomit 
or feel nausea anymore. After five days of steroid therapy, his total bilirubin level became 10.83 g/dL. He was 
discharged home with steroid therapy and steroid was tapered off during follow-up in the clinic.
Prolonged cholestasis is one of atypical manifestation of hepatitis A which is rarely found. Cholestasis 
increases morbidity and prolongs hospitalization. Steroid therapy decreased bilirubin level and gave clinical 
improvement to the patient.
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ABSTRAK
Hepatitis A merupakan virus RNA yang mempunyai sifat stabil dalam temperatur sedang dan pH rendah. 
Karakteristik ini memungkinkan virus mampu bertahan hidup dalam lingkungan dan ditransmisikan melalui oro-fekal.
Seorang laki-laki usia 20 tahun datang dengan keluhan tubuh kuning dan gatal sejak lima minggu sebelum 
masuk rumah sakit. Dari hasil anamnesis, pemeriksaan fisik dan laboratorium, pasien didiagnosa hepatitis A tipe 
kolestatik. Pada hasil pemeriksaan laboratorium ditemukan peningkatan bilirubin total 27,4 g/dL, bilirubin direk 
21,2 g/dL dan indirek 6,2 g/dL, ALT 95 U/L, AST 134 U/L, ALP 221 U/L, dan gamma GT 17 U/L. Pada pemeriksaan 
ultrasonografi menunjukkan gambaran hepatomegali ringan non spesifik tanpa pelebaran duktus kanalikuli maupun 
pelebaran duktus bilier komunis. Pasien mendapatkan terapi simtomatik asam ursdeoksikolik 300 mg dua kali 
sehari untuk mengatasi gatal dan diberi steroid 0.5-1 mg/kg berat badan. Setelah 5 hari pemberian kadar bilirubin 
total menurun menjadi 10,83 g/dL, keluhan mual dan muntah tidak ditemukan lagi. Pasien dipulangkan dengan 
terapi steroid dan dilakukan penurunan dosis steroid secara bertahap selama masa rawat jalan. 
Kolestasis hepatitis A merupakan salah satu manifestasi atipikal yang jarang ditemukan. Kolestasis 
meningkatkan morbiditas dan masa rawat di rumah sakit. Pemberian kortikosteroid dapat menurunkan bilirubin, 
mempercepat penyembuhan, dan perbaikan gejala klinis pada pasien.
Kata kunci: hepatitis A, kolestasis, terapi steroid
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INTRODUCTION
Hepatitis A virus (HAV), a positive-strand RNA 
virus, is stable at moderate temperature and low 
pH.These characteristics allow the virus to survive in the 
environment and be transmitted through fecal-oral route. 
HAV is still an important etiology of acute viral hepatitis 
worldwide. Poor sanitation, contaminated food, and 
poor personal hygiene contributes to the transmission.1 
This viral can be inactivated by boiling for one minute, 
use of formaldehyde, chlorine and ultraviolet radiation. 
Clinical manifestation of hepatitis A depend on the age 
of the host; less than 30% of infected young children 
showed symptomatic hepatitis, while about 80% of 
infected adults manifests as severe acute hepatitis.with 
remarkably elevated serum amino transferase.2
Clinical spectrums of HAV infection range from 
asymptomatic infection to fulminant hepatitis. Its 
replication is limited to the liver, but the virus is 
present in the liver, bile, stools, and blood during the 
late incubation period and acute pre-icteric phase of 
illness. Despite persistence of virus in the liver, viral 
shedding in feces, viremia, and infectivity diminish 
rapidly once jaundice becomes apparent. Typical 
manifestation of HAV infection starts with incubation 
period for about 2-7 week, including fever, malaise, 
nausea, vomiting, abdominal discomfort, dark urine 
and jaundice. Jaundice could be seen in infected adult 
with concentration of bilirubin below 10 mg/dL, and 
begin to recover in two weeks.3
Clinical illness and laboratory abnormalities 
recover within two months from the onset of disease. 
No evidence of chronic infection seen in HAV infection 
but some cases continue to prolonged cholestatic form 
or relapsing disease lasting up to six months. There 
have been reports on atypical manifestation of HAV, 
including prolonged cholestasis, acute kidney injury, 
recurrent hepatitis, hemolytic anemia, or other extra-
hepatic manifestation. 
In this case report we will discuss about diagnosis 
and management of patient with prolonged cholestatis 
HAV. From the literature,itis reported that this 
manifestation occurs rare only at a rate of 0.4-0.8%.3 
Effective and efficient treatment is needed in order to 
reduce morbidity, but no differences in mortality.
CASE ILLUSTRATION
Twenty-year-old male came with jaundice and 
itchy skin since one month before admission. He had 
nausea and vomit followed with fever and fatigue since 
five weeks ago. He felt fever all day long, gradually 
increased every day, but no chills. Then, he realized 
that he had jaundice and dark urine. He did not have 
either pale or black stool and felt itchy skin. He also 
complained of continuous, dull right upper abdominal 
pain. The laboratory result diagnose as hepatitis. After 
several follow up in the clinic, he felt less nausea and 
vomit and no fever. But he still complained of jaundice 
and itchy skin. His blood test showed elevated bilirubin 
level.
On physical examination, patient had normal 
vital signs, icteric sclera, but no anemic conjunctiva. 
There was no spider nevi. Heart and lung sounds were 
clear. He had hepatomegaly, one finger below costal 
arch with blunt edge, elastic in consistency, smooth 
surface and tenderness. There was no ascites and 
splenomegaly. He did not have clubbing finger and 
leg swelling. His extremity was warm.
Laboratory result showed hemoglobin 16.5 g/dL, 
leukocytes 7,800/μL and platelet 254,000/μL, total 
bilirubin 8.8 g/dL, direct bilirubin 7.1 g/dL, indirect 
bilirubin 1.5 g/dL, alanin-aminotransferase (ALT) 
64 U/L, and aspartate transaminase (AST) 180 U/L. 
Six days later because of his worsen jaundice, the 
laboratory result showed elevated total bilirubin 27.4 
g/dL, direct bilirubin 21.2 g/dL, indirect bilirubin 6.2 
g/dL, ALT 95 U/L, AST 134 U/L, alkaline phosphatase 
(ALP) 221 U/L, and gamma GT 17 U/L. His hepatitis 
serology showed reactive IgM anti HAV with index 
7.85, and non reactive to HbsAg, anti-Hbc and anti-
HCV. The laboratory result revealed high bilirubin 
level with minimally elevated AST and ALT. His 
ultrasound showed mild, non-specific hepatomegaly 
without canaliculi and common bile duct dilatation.
He was diagnosed as hepatitis A cholestasis type 
according to his anamnesis, physical examination, 
laboratory result, and ultrasound. He never had hepatitis 
before, no history of sexual multi-partner, intravenous 
drug-abuse, and herbal medicine consumption. He did 
not lose weight and appetite. There is no history of 
malignancy in the family.
He got symptomatic therapy with ursodeoxycholic 
acid (UDCA) 300 mg twice daily for his itchy skin. 
He did not vomit or feel nausea anymore. His bilirubin 
test showed total bilirubin was decreased from 29.93 
g/dL to 25.4 mg/dL and 19.44 g/dL in the fifth day of 
treatment. Therefore, steroid therapy was not added 
to his treatment. However, his laboratory result then 
showed elevated total bilirubin level on the seventh 
and tenth day, respectively 21.55 g/dL and 23.83 g/
dL. He got steroid therapy 0.5-1 mg/kg per day on the 
tenth day. After five days of steroid therapy, his total 
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bilirubin level became 10.83 g/dL. He was discharged 
with steroid therapy and steroid was tappered off 
during follow-up in the clinic. Patient did not check 
laboratory tests as adviced but from follow up 4 weeks 
later, he did not complain any jaundice. 
Figure 1. Patient’s bilirubin level
for several months, rarely for 6–12 months. During 
the convalescence, however, anti HAV of the igG 
class becomes the predominant antibody.Therefore the 
diagnosis of hepatitis A is made during acute illness by 
demonstrating anti HAV of the IgM class.1
Classic and atypical hepatitis usually begins with 
prodromal symptoms, followed with jaundice and 
elevated liver enzyme. It happened to this patient. 
He started to feel nausea and vomit followed with 
jaundice and dark urine. A study conducted by Tong et 
al revealed that the most common symptoms of patient 
with hepatitis A are dark urine (81%), fatigue (80%), 
gastrointestinal upset and fever (58%). The most 
common signs are hepatomegaly (78%) and jaundice 
(71%).5 This patient had all this signs and symptoms. 
But during follow up at the ward, the only signs and 
symptoms found were jaundice and hepatomegaly.
The patient’s bilirubin level showed elevation 
and fluctuation since the initial treatment, but the 
transaminase level decreased to normal level on 
the discharge day. Transaminase serum level never 
elevated up to three times as high as the normal limit 
than normal while patient was hospitalized. Patient 
with cholestasis can have diarrhea, weight lost, and 
pruritic skin. But he only complained of pruritic skin 
without diarrhea. Pruritic skin is caused by the bile 
deposition in the skin.
Incidence of intrahepatic cholestasis in hepatitis A 
is 0.4-0.8%. Another study in Korea showed higher 
incidence which was 4.7%, even previous study 
showed 7% incidence of prolonged cholestasis due to 
hepatitis A infection with bilirubin level 8-38 mg/dL 
(average is 20) with time duration 12-16 weeks after 
onset.5 In patient with classic manifestation of hepatitis 
A, bilirubin levels returned to nearly normal levelby 
mean of 5.3 weeks. 
A prospective study in Korea found out that risk 
factors for prolonged cholestasis were older patients 
(35 vs 30 year old), hepatitis B carrier, higher level 
bilirubin (15.7 mg/dL vs. 6.4 mg/dL) and in patients 
with low albumin level (3.5 g/dL vs. 3.7 g/dL). Time 
duration from admission to cure and improvement 
liver function in prolonged cholestasis can be up to 70 
days compared to patients without cholestasis which 
is 36 days (p < 0.01). Chronic hepatitis B infection, 
prolonged prothrombine time/INR (1.6 vs. 1.2) and 
higher bilirubin level are associated with prolonged 
cholestasis. Eventhough cholestasis increase morbidity 
but patient can betotally cured.4 During the illness, 
the peak bilirubin level of this patient was 29.93 mg/
dL. This finding was in concordance to the study in 
DISCUSSION
Prolonged cholestasis is one of atypical 
manifestations of hepatitis A infection. Appropriate 
diagnosis and treatment is needed because this 
manifestation will increase morbidity and medical cost.
Prolonged cholestasis is defined as elevated total 
bilirubin > 5 mg/dL more than 4 weeks after diagnosis.4 
Previous definition of acute cholestatic hepatitis A was 
based on the following criteria: clinically jaundice for 
at least 12 weeks, with a peak serum bilirubin greater 
than 10 mg/dL at a time when the serum aspartate 
aminotransferase level was rapidly declining.3 But we 
can not wait until 12 weeks because it will increase 
morbidity, so if any patient has a hepatitis A infection 
and jaundice more than four weeks we should start to 
think about prolonged cholestatis. Signs and symptoms 
of prolonged cholestasis are pruritic skin, fatigue, loose 
stool and weight lost.2 HAV RNA could be detectable 
until 20 days after infection.2 These symptoms were 
similar to our patient who admitted to hospital with 
chief complaint of jaundice for four weeks. The patient 
felt nausea and vomit followed by jaundice. He was 
diagnosed as hepatitis A in the clinic. The laboratory 
result showed elevated total bilirubin level 8.8 g/dL, 
elevated liver transaminase and reactive IgM HAV. 
His bilirubin level was still elevated after 4 weeks 
with the highest level was 29.93 g/dL. Antibodies 
to HAV can be detected during acute illness when 
serum aminotransferase activity is elevated and fecal 
HAV shedding is still occurring. Thus early antibody 
response is predominantly of the IgM class and persists 
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Korea, that revealed patient significantly predispose 
to complicate to prolonged cholestasis. 
In this case abdominal ultrasonography (USG) 
showed mild hepatomegaly without dilatation of intra- 
and extrahepatic bile ducts. With this USG, we could 
be sure that there was no extrahepatic obstruction. 
No further evaluation was needed because it was 
considered time-consuming, costly and involved 
potential risk.3
Cholestasis happens because of some mechanism, 
including decreased bilirubin uptake, conjugation 
dysfunction, bilirubin excretion dysfunction and 
biliary obstruction. In hepatitis A, cholestasis happens 
because of inflammatory process. Endotoxin and pro 
inflammatory cytokines are released from liver and also 
as systemic response. TNF alfa and IL-1 inhibit mrp2 
(multidrug-resistance associated protein 2), one of the 
proteins that has role in bilirubin excretion.6
Prolonged cholestasis is also caused by host factor 
or severe destruction in liver cells in the beginning 
of infection. It is true because there is also prolonged 
prothrombin time and elevated bilirubin in patient with 
prolonged cholestasis. It can be also caused by the virus 
itself that inhibits bile salt transport eventhough the 
mechanism is unknown yet. In patients with prolonged 
cholestasis due to hepatitis A, the duration of HAV 
viremia was longer than the classic one, so it makes 
probably direct effect on the transporters related to 
cholestatis.6
UDCA is the main therapy for chronic cholestasis 
such as in patient with primary billiary cirrhosis (PBC). 
UDCA has protective effect on bile salt by increasing 
hydrophilic fraction so it becomes more water-soluble 
and has role in membrane stability. A randomized-study 
wasconducted in 79 patients treated with UDCA and 
placebo in 3 weeks. Patients who got UDCA had earlier 
decreased bilirubin, gamma GT, alkaline phospatase 
and transaminase level than placebo. But statistically 
not significant for transaminase level.7
The patient received ursodeoxy cholic acid 300 mg 
twice daily in the tenth day of hospitalization because 
he complained of pruritic skin and elevated bilirubin 
level. The rationale for this treatment was based on 
the studies that showed beneficial effects on serum 
biochemistries. This agent also relieves pruritus in 
some patients and is well tolerated with insignificant 
side effects, apart from diarrhea, which occurs in 
less than 2% of patients. It is well known that UDCA 
administration may prevent or reduce damage to liver 
cells and may also reduce cholestasis induced by high 
concentration of hydrophobic bile acids. In this case 
the bilirubin level was slightly decreased but increased 
again with slight clinical improvement. 
There was an elevated bilirubin level in the tenth 
day of therapy but no biliary obstruction was found, 
so then steroid therapy was initiated in this patient. 
Some case reports and randomized-placebo control 
trial showed steroid could help to improve cholestasis 
A case-report from India, a child with jaundice for six 
weeks and also with pruritic skin in the last two weeks 
showed elevated bilirubin level in a serial laboratory 
test. Serology test showed hepatitis A infection. The 
patient was diagnosed hepatitis A with prolonged 
cholestasis because there was no improvement in 
jaundice. The patient was given steroid therapy 
with prednisolone 60 mg. After three days of steroid 
therapy, there was clinical improvement with decreased 
bilirubin level. After two weeks of steroid, the dosage 
was tapered into 30 mg/day and gradually tapered 
off in two weeks. After 4 weeks of steroid therapy, 
bilirubin level decreased to 2.6 mg/dL.8 In this case 
corticosteroid could improve clinical manifestation 
and relieve pruritus. No adverse reaction was reported.
Three case reports from Korea stated about steroid 
therapy as management of prolonged cholestasis in 
hepatitis A. The first case was about 40 year-old-male 
diagnosed ashepatitis A, with jaundice until 4 weeks 
after diagnosis. Bilirubin level was increased as high 
as 23.5 mg/dL. The patient got prednisolone 30 mg/
day. After 13 days of steroid therapy, total bilirubin was 
Figure 2. Ultrasound showed no dilated ducts
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decreased to 11.3 mg/dL. After 4 weeks of prednisolone 
therapy, the dose was tapered gradually to 10 mg every 
two weeks. Bilirubin level in the eighth week was 1.7 
mg/dL. Second case was about 35 year-old-male with 
the same symptoms. His serial bilirubin tests showed 
increased bilirubin level as high as 31.79 mg/dL. After 4 
weeks of conventional treatment without improvement, 
the patient got prednisolone 30 mg/day. On the 23rd 
day following administration of steroid, total bilirubin 
declined to 13.2 mg/dL. They stopped prednisolone 
in the twelfth week after gradual tapering since fourth 
week. Bilirubin level decreased to 1.09 mg/dL in the 
twelfth week. The third case was about 42 year-old 
male. He was referred after 4 weeks of in-hospital 
treatment with highest bilirubin level was 31.5 mg/dL 
and also be given the same dosage of prednisolone. 
He got steroid therapy for nine weeks and his bilirubin 
level decreased to 0.32 mg/dL. Serial bilirubin level 
tests after steroid therapy showed clinical significance. 
Bilirubin level was half than maximum level in the 
13th, 23rd and 8th day in every case.6 These case reports 
were similar to our patient, which had jaundice for 
4 weeks before admission and started conventional 
therapy for the next ten days, because no or less clinical 
improvement, the patient was given steroid and in the 
fifth day bilirubin level was decreased to half. From 
this case, we knew that corticosteroid could be given 
to patients with prolonged jaundice which showed no 
improvement with conventional therapy.
A randomized study was held to evaluate efficacy 
of steroid therapy as management of prolonged 
cholestasis in hepatitis A. This study compared UDCA 
and prednisolone (group A) with UDCA and placebo 
(grup B). From 84 patients with hepatitis A, 21 of 
them were diagnosed as prolonged cholestasis. Eleven 
patients were given UDCA and prednisolone and 10 
patients were given UDCA and placebo.9
Average bilirubin level in group A was 29.4 mg/
dL with no significant difference compared to group 
B which was 28.6 mg/dL. Bilirubin level was checked 
in day 3, 7, 14, 21, 28, 35, 42, and 49. The decrease 
in bilirubin in group A (cumulative mean) at day 3, 
7, 14, 21, 28, 35, 42, 49 was 20.1%, 45.6%, 58.6%, 
64.6%, 71.7%, 76.1%, 80.5% and 86.4%, respectively. 
The mean time for bilirubin normalization was 44 
days (range 28–84 days). In group B who got UDCA 
and placebo, bilirubin level was 2.1%, 5.9%, 11.9%, 
25.1%, 29.3%, 33.3%, and 38.5%, in average 91 days 
(74-138 days), with p < 0.05. Pruritic skin got better 
in day 5 (4-8) in group A compared to group B in 
day 24 (18-45). There was no side effects of steroid 
found in this study.9 The use of corticosteroid could 
improve clinical manifestations significantly including 
decreased bilirubin level and relieved pruritus. 
Study in Korea about the clinical manifestations of 
acute cholestatic hepatitis was presented recently. From 
21 patients,mean value of total bilirubin was 17.2 mg/
dL and the mean time for bilirubin to be normalized 
was 93 days. So it was suggested that severe cholestasis 
would take longer duration to be cured by supportive 
treatment only.10
TNF alfa and IL-1 have important role in 
pathogenesis of prolonged cholestasis in hepatitis A. 
It is therefore conceivable that cholestasis associated 
with this inflammatory process can be improved by the 
administration of steroids.5 A study on steroid showed 
that dexamethasone inhibited TNF alfa and IL-1 
synthesis, so dexamethasone could prevent impairment 
in the function of mrp2 in the canaliculi of endotoxemic 
rats. Dexamethasone has the capability in induction of 
expression mrp2 twice compared to normal liver cells 
and facilitates bilirubin metabolism.6
Actually the presence of persistent cholestasis can 
still be managed symptomatically, but this frequently 
lengthens hospital stay and causes higher medical 
expenses and social economic loss. Therefore, it is 
imperative that methods are developed to improve 
clinical courses more promptly in patients with acute 
viral hepatitis A complicated by persistent uncontrolled 
cholestasis. The use of corticosteroids has not been 
shown to influence the ultimately favorable outcome of 
patients with cholestatic viral hepatitis. Nevertheless, a 
salutary role for steroids in the treatment of some forms 
of cholestatic hepatitis has been previously recognized. 
The decision to begin steroids was based on the 
often debilitating symptoms associated prolonged 
cholestasis. Prednisone or corticosteroid generally 
resulted in symptomatic relief and rapid initial drop 
in serum bilirubin levels.3
Therefore, there are still controversies on the efficacy 
of steroid therapy. It was reported that cholestasis 
spontaneously resolves although corticosteroids may 
hasten the resolution, but it may predispose the patient 
to develop a relapse of the hepatitis. 
This patient has no contraindicated for steroid 
therapy like prolonged, so this patient got steroid 
therapy according to literature above. The patient 
had total 4-5 week jaundice before admitted to our 
hospital, and despite additional 10 days of conservative 
therapy, the total bilirubin was still elevated up to 
23.83 mg/dL. Methyl prednisolone was initiated at 32 
mg in divided dose. Steroid improves edema caused 
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by inflammation in liver cells which caused biliary 
obstruction. Five days after steroid therapy, bilirubin 
level decreased from 23.83 g/day to 10.83 mg/dL with 
clinical improvement. Total bilirubin decreased to 50% 
before steroid therapy. The patient did not complain 
of itchy skin, nausea and vomit anymore. He was 
discharged in day 16.
Prolonged cholestasis is one of atypical manifestation 
of hepatitis A which is rarely found. Cholestasis 
increases morbidity and prolonged hospitalization. 
Steroid therapy decreased bilirubin level and gave 
clinical improvement to the patient.
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